ChiCTR2100050335
Untitled Trial
Esketamine reactivates the efficacy of antidepressants in the treatment of major depressive disorder: a double blind, randomized, controlled trial
Beijing Anding Hospital, Capital Medical University·Phase 4·Chinese Clinical Trial RegistryRecruiting
View on Chinese Clinical Trial Registry →Study focus
- Disease/Condition
- Depressive Disorder
Sponsor & location
- Primary sponsor
- Beijing Anding Hospital, Capital Medical University
- Funder
- Self financed
- Location
- China
Timeline & enrollment
- Phase
- Phase 4
- Start date
- N/A
- End date
- Sep 01, 2022
ICD-10 classifications
Depressive conduct disorderRecurrent depressive disorder, unspecifiedRecurrent depressive disorderOther recurrent depressive disordersRecurrent depressive disorder, currently in remission
Data source
- Registry
- Chinese Clinical Trial Registry
- Trial ID
- ChiCTR2100050335
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for ChiCTR2100050335 through Pure Global AI's free database. This Phase 4 trial is sponsored by Beijing Anding Hospital, Capital Medical University and is currently Recruiting. The study focuses on Depressive Disorder.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Chinese Clinical Trial Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.